Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: A double-blind placebo-controlled, fixed dose, randomized study

Journal of Sexual Medicine

Volumn 5, Issue 4, 2008, Pages 887-897

  Safarinejad, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Arousal Disorder; Bremelanotide; Melanocortin Agonist; Treatment

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; BREMELANOTIDE; MELANOCORTIN RECEPTOR AGONIST; PLACEBO; PROLACTIN; SEX HORMONE; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FEMALE SEXUAL FUNCTION INDEX; FLUSHING; HEADACHE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL AROUSAL DISORDER; SEXUAL SATISFACTION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINALYSIS;

EID: 41549146270     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00698.x     Document Type: Article

References (38)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999; 281: 537-44.
2. Graziottin A. Prevalence and evaluation of sexual health problems-HSDD in Europe. J Sex Med 2007; 4 (3 suppl): 211-9.
3. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med 2007; 4 (3 suppl): 235-53.
4. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, Goldstein I, Graziottin A, Heiman J, Laan E, Leiblum S, Padma-Nathan H, Rosen R, Segraves K, Segraves RT, Shabsigh R, Sipski M, Wagner G, Whipple B. Report of the international development conference on female sexual function: Definitions and classification. J Urol 2000; 163: 888-93.
5. American Psychiatric Association. DSM-IV: Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Press; 1994.
6. Basson R. Clinical practice. Sexual desire and arousal disorders in women. N Engl J Med 2006; 354: 1497-506.
7. Frank E, Anderson C, Rubinstein D. Frequency of sexual dysfunction in "normal" couples. N Engl J Med 1978; 299: 111-5.
8. Rosen RC, Taylor JF, Leiblum SR, Bachmann GA. Prevalence of sexual dysfunction in women: Results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther 1993; 19: 171-88.
9. Basson R. Women's sexual dysfunction: Revised and expanded definitions. CMAJ 2005; 172: 1327-33.
10. DeRogatis LR, Burnett AL. Key methodological issues in sexual medicine research. J Sex Med 2007; 4: 527-37.
11. Laan E, van Lunsen RH, Everaerd W, Riley A, Scott E, Boolell M. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gend Based Med 2002; 11: 357-65.
12. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11: 367-77.
13. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641-6.
14. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005; 26: 1687-9.
15. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003; 994: 96-102.
16. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993; 268: 8246-50.
17. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174-9.
18. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 628-38.
19. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA 2004; 101: 10201-4.
20. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004; 16: 135-42.
21. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16: 51-9.
22. Hayes RD, Bennett C, Dennerstein L, Gurrin L, Fairley C. Modeling response rates in surveys of female sexual difficulty and dysfunction. J Sex Med 2007; 4: 286-95.
23. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208.
24. Kim SW, Paick JS. Short-term analysis of the effects of as needed use of sertraline at 5 pm for the treatment of premature ejaculation. Urology 1999; 54: 544-7.
25. Glantz SA. Primer of Biostatistics, 4th ed. New York: McGraw-Hill; 1997.
26. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: Classifications and definitions. J Sex Med 2007; 4: 241-50.
27. Coyne KS, Margolis MK, Brewster-Jordan J, Sutherland SE, Bavendam T, Rogers RG. Evaluating the impact of overactive bladder on sexual health in women: What is relevant? J Sex Med 2007; 4: 124-36.
28. McCall K, Meston C. Cues resulting in desire for sexual activity in women. J Sex Med 2006; 3: 838-52.
29. Bancroft J. Sexual arousal. In: Nadel L, ed. Encyclopedia of cognitive science. London: Wiley; 2002: 1165-8.
30. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: Prevalence and associated risk factors. Int J Impot Res 2006; 18: 382-95.
31. Leiblum SR, Koochaki PE, Rosen RC. Self-reported distress associated with decreased interest in sex in women. Paper presented at Second International Consultation on Erectile and Sexual Dysfunctions, Paris, France, June 30, 2003.
32. Hallam-Jones R, Wylie K. Traditional dance - a treatment for sexual arousal problems? J Sex Relationship Ther 2001; 16: 377-80.
33. Berman JR, Bassuk J. Physiology and pathophysiology of female sexual function. World J Urol 2002; 20: 111-8.
34. Laan E, van Lunsen RH, Everaerd W, Riley A, Scott E, Boolell M. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gend Based Med 2002; 11: 357-65.
35. Berman JR, Berman LA, Toler SM, Gill J, Haughie S, Sildenafil Study Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. J Urol 2003; 170: 2333-8.
36. Kielbasa LA, Daniel KL. Topical alprostadil treatment of female sexual arousal disorder. Ann Pharmacother 2006; 40: 1369-76.
37. Sadovsky R, Alam W, Enecilla M, Cosiquien R, Tipu O, Etheridge-Otey J. Sexual problems among a specific population of minority women aged 40-80 years attending a primary care practice. J Sex Med 2006; 3: 795-803.
38. Nijland E, Davis S, Laan E, Schultz WW. Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 2006; 3: 763-77.